The UNITO team (D. Oddo et al.) has just published Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer in the British Journal of Cancer (DOI: 10.1038/bjc.2017.196). Background: Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal cancer carrying BRAFV600E and MET amplification. However, after 4 months, acquired […]
This author has yet to write their bio.Meanwhile lets just say that we are proud mercuric contributed a whooping 46 entries.
Entries by mercuric
MErCuRIC researchers have recently published a review in Nature Reviews Clinical Oncology. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges Conor A. Bradley, Manuel Salto-Tellez, Pierre Laurent-Puig, Alberto Bardelli, Christian Rolfo, Josep Tabernero, Hajrah A. Khawaja, Mark Lawler, Patrick G. Johnston, Sandra Van Schaeybroeck & on behalf of the MErCuRIC consortium Data from many preclinical studies, including those using cellular models of colorectal, gastric, gastro-oesophageal and […]
EUPATI is hosting a webinar on Guidance for Patient Involvement in Ethical Review of Clinical Trials, 29 May 2017 – 17:00 to 18:30 CET. You can learn more and register here. More information on the guidance developed by EUPATI can be found here.
Initiated in 2011 by the EurocanPlatform and since 2016 organized under the umbrella of Cancer Core Europe, the Summer School in Translational Cancer Research will once again take place in Portugal in Albufeira, 16 – 20 October, 2017. The registration deadline is 30 June 2017. You can learn more about the course here: https://dktk.dkfz.de/en/training/dktk-summer-school/introdution.
Applications are now being accepted for the third EUPATI Expert Training Course. The EUPATI Training Course Patient Experts in Medicines Research & Development is an exciting and unique opportunity offering patient advocates expert-level training in medicines research and development, specifically tailored for them. The application deadline is 31 March 2017.
Congratulations to Margaret Grayson, our MErCuRIC Patient Representative, who received a ‘Special Commendation’ for Research Engagement from Cancer Research UK in 2016!
The MErCuRIC team met at UZA in Antwerp for our Year 3 meeting (05 – 06 Dec 2016). We discussed progress in the Phase I trial from the previous year, and mapped our clinical and translational activities for the coming year. As the dose escalation phase I study draws to a close, we are planning […]
The latest newsletter from EUPATI is now available. This issue covers an update on national activities across Europe and metrics on use of the EUPATI website.
MErCuRIC results were presented in a poster at the NCRI Cancer Conference in Liverpool, UK on 08 Nov 2016 (Session B, 08:15-11:00). The conference ‘showcases the latest basic, translational and clinical cancer research. It brings researchers together to share ideas and develop collaborations.’ ‘MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced […]
The latest newsletter from EUPATI is now available. This issue covers an update on national activities in 18 countries and information on the upcoming EUPATI 2016 conference All Aboard to a Better Health Future on 14 Dec 2016.
- Reflections from EAPM 2017 where MErCuRIC PPI was HighlightedDecember 14, 2017 - 8:11 am
- EuropaColon Patients’ Survey on The Unmet Needs of Patients Living with Metastatic Colorectal CancerDecember 4, 2017 - 3:35 pm
- MErCuRIC team from the Università degli Studi di Torino publish in NatureNovember 30, 2017 - 8:54 am
MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.